E25.0 Congenital adrenogenital disorders associated with enzyme deficiency

Name of the Condition

• Congenital Adrenogenital Disorders Associated with Enzyme Deficiency (ICD-10 Code: E25.0)

Summary

Congenital adrenogenital disorders associated with enzyme deficiency involve genetic defects in adrenal steroid synthesis, leading to hormonal imbalances. These conditions disrupt normal development, particularly affecting sexual differentiation and electrolyte balance. The enzyme deficiencies impair the production of cortisol, aldosterone, or androgens, resulting in clinical manifestations that may present at birth or during early childhood.

Causes

The disorders are caused by inherited genetic mutations affecting enzymes in the adrenal steroid pathway. Common deficiencies include 21-hydroxylase, 11β-hydroxylase, or other enzymes critical for cortisol or aldosterone synthesis. These mutations disrupt hormone production, leading to either excess androgen or insufficient mineralocorticoid/corticosteroid levels, which drive the clinical symptoms.

Risk Factors

• Genetic inheritance, as most forms are autosomal recessive.
• Family history of adrenal enzyme deficiencies.
• Consanguinity, increasing the likelihood of recessive gene transmission.

Symptoms

• Ambiguous genitalia in newborns (more common in genetic males).
• Virilization in females, such as clitoromegaly or early pubic hair.
• Electrolyte imbalances, including hyponatremia or hyperkalemia (in salt-wasting forms).
• Failure to thrive or dehydration due to aldosterone deficiency.
• Accelerated growth with advanced bone age in children.

Diagnosis

Diagnosis involves measuring serum electrolytes, cortisol, and adrenal hormone precursors (e.g., 17-hydroxyprogesterone) via blood tests. Genetic testing confirms specific enzyme deficiencies. Newborn screening may detect elevated 17-hydroxyprogesterone in some regions. Imaging of the adrenal glands (e.g., ultrasound) is rarely needed but may assess gland size or structure.

Treatment Options

Treatment focuses on hormone replacement to correct deficiencies and suppress excess androgens. This includes glucocorticoids (e.g., hydrocortisone) to replace cortisol and mineralocorticoids (e.g., fludrocortisone) for salt-wasting forms. Doses are adjusted based on growth, electrolyte levels, and clinical response. Surgical correction may address ambiguous genitalia in severe cases.

Prognosis and Follow-Up

With early diagnosis and consistent treatment, prognosis is generally good. Lifelong hormone management is required to prevent adrenal crises and support normal development. Regular monitoring of growth, bone age, and hormone levels is essential. Untreated cases may lead to adrenal insufficiency, infertility, or psychosocial challenges related to gender identity.

Complications

• Adrenal crisis (life-threatening cortisol deficiency).
• Infertility or reproductive issues in adulthood.
• Short stature or delayed puberty if treatment is suboptimal.
• Psychological distress related to gender identity or appearance.

Lifestyle & Prevention

• Adherence to prescribed hormone regimens to prevent crises.
• Wearing medical alert identification for emergency situations.
• Avoiding dehydration or stress without dose adjustments.
• Genetic counseling for families with affected children.

When to Seek Professional Help

Seek immediate care for symptoms of adrenal crisis: severe fatigue, vomiting, low blood pressure, or confusion. Routine follow-up is needed for growth concerns, electrolyte abnormalities, or unexplained virilization. Consult a pediatric endocrinologist for diagnosis and management.

Tips for Medical Coders

Document the specific enzyme deficiency (e.g., 21-hydroxylase) when available, as it may support coding specificity. Include details on salt-wasting versus non-salt-wasting forms, as these affect clinical management and coding accuracy. Ensure documentation aligns with the ICD-10-CM guidelines for congenital adrenal enzyme deficiencies to justify the E25.0 code.